Xamoterol (BioDeep_00000008863)
代谢物信息卡片
Xamoterol hemifumarate
化学式: C16H25N3O5 (339.1794)
中文名称: 富马酸扎莫特罗
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: c1cc(ccc1O)OCC(CNCCNC(=O)N1CCOCC1)O
InChI: InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)
描述信息
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists
Same as: D06328
同义名列表
3 个代谢物同义名
数据库引用编号
16 个数据库交叉引用编号
- ChEBI: CHEBI:10055
- KEGG: C11775
- KEGGdrug: D06328
- PubChem: 155774
- Metlin: METLIN69212
- DrugBank: DB13781
- ChEMBL: CHEMBL75753
- MeSH: Xamoterol
- CAS: 69630-08-6
- CAS: 81801-12-9
- CAS: 73210-73-8
- PMhub: MS000022567
- PubChem: 13939
- NIKKAJI: J260.445K
- RefMet: Xamoterol
- KNApSAcK: 10055
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Joëlle Huet, Emmanuel Jean Teinkela Mbosso, Sameh Soror, Franck Meyer, Yvan Looze, René Wintjens, Alexandre Wohlkönig. High-resolution structure of a papaya plant-defense barwin-like protein solved by in-house sulfur-SAD phasing.
Acta crystallographica. Section D, Biological crystallography.
2013 Oct; 69(Pt 10):2017-26. doi:
10.1107/s0907444913018015. [PMID: 24100320] - C O Uhiara, S P H Alexander, R E Roberts. Effect of inhibition of extracellular signal-regulated kinase on relaxations to beta-adrenoceptor agonists in porcine isolated blood vessels.
British journal of pharmacology.
2009 Dec; 158(7):1713-9. doi:
10.1111/j.1476-5381.2009.00435.x. [PMID: 19912229] - Kimberly P Williams, Jena J Steinle. Maintenance of beta-adrenergic receptor signaling can reduce Fas signaling in human retinal endothelial cells.
Experimental eye research.
2009 Oct; 89(4):448-55. doi:
10.1016/j.exer.2009.04.015. [PMID: 19523948] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Arnaud Robinet, Loubna Alouane, Guillaume Hoizey, Hervé Millart. Advanced-glycation end products (AGEs) derived from glycated albumin suppress early beta1-adrenergic preconditioning.
Fundamental & clinical pharmacology.
2007 Feb; 21(1):35-43. doi:
10.1111/j.1472-8206.2006.00451.x. [PMID: 17227443] - Hans Persson, Karin Andréasson, Thomas Kahan, Sven V Eriksson, Bo Tidgren, Paul Hjemdahl, Christian Hall, Leif Erhardt. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists.
European journal of heart failure.
2002 Jan; 4(1):73-82. doi:
10.1016/s1388-9842(01)00196-9. [PMID: 11812667] - J Bergler-Klein, H Sochor, H Pouleur, R Pacher, G Porenta, D Glogar. Safety of concomitant potassium-sparing diuretics in angiotensin-converting enzyme inhibitor therapy in severe congestive heart failure. Xamoterol in Severe Heart Failure Study Group.
Journal of cardiovascular pharmacology.
1994 Aug; 24(2):194-8. doi:
. [PMID: 7526050] - H E Bøtker, H K Jensen, L R Krusell, E V Sørensen. Renal effects of xamoterol in patients with moderate heart failure.
Cardiovascular drugs and therapy.
1993 Feb; 7(1):111-6. doi:
10.1007/bf00878318. [PMID: 8485065] - C A Haffner, M J Kendall, S Maxwell, B Hughes. The lipolytic effect of beta 1- and beta 2-adrenoceptor activation in healthy human volunteers.
British journal of clinical pharmacology.
1993 Jan; 35(1):35-9. doi:
10.1111/j.1365-2125.1993.tb05667.x. [PMID: 8383517] - R J MacFadyen. Role of the circulating and tissue-based renin-angiotensin system in the development of heart failure: implications for therapy.
Cardiology.
1993; 83(1-2):38-48. doi:
10.1159/000175946. [PMID: 8261485] - A Obara, H Yamashita, S Onodera, O Yahara, H Honda, N Hasebe. Effect of xamoterol in Shy-Drager syndrome.
Circulation.
1992 Feb; 85(2):606-11. doi:
10.1161/01.cir.85.2.606. [PMID: 1346511] - H Ozaki, H Sato, M Hori, T Matsuyama, K Imai, H Yokoyama, A Kitabatake, M Inoue, T Kamada. Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.
European journal of clinical pharmacology.
1992; 43(5):455-61. doi:
10.1007/bf02285085. [PMID: 1362383] - P J Leslie, C Thompson, B F Clarke, D J Ewing. A double-blind crossover study of oral xamoterol in postural hypotension due to diabetic autonomic neuropathy.
Clinical autonomic research : official journal of the Clinical Autonomic Research Society.
1991 Jun; 1(2):119-23. doi:
10.1007/bf01826207. [PMID: 1688039] - W Kupper. Interrupting the adaptive changes in congestive heart failure.
The American journal of cardiology.
1991 May; 67(12):20C-22C. doi:
10.1016/0002-9149(91)90070-2. [PMID: 1673586] - M J Jamieson, J Webster, G Fowler, J Rawles, F W Smith, J C Petrie. A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure.
British journal of clinical pharmacology.
1991 Mar; 31(3):305-12. doi:
10.1111/j.1365-2125.1991.tb05534.x. [PMID: 1675867] - E V Sørensen, H K Jensen, O Faergeman. Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers.
European journal of clinical pharmacology.
1991; 41(1):51-5. doi:
10.1007/bf00280106. [PMID: 1685993] - B Tomlinson, J M Cruickshank, Y Hayes, J C Renondin, J B Lui, B R Graham, A Jones, A D Lewis, B N Prichard. Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.
British journal of clinical pharmacology.
1990 Nov; 30(5):665-72. doi:
10.1111/j.1365-2125.1990.tb03834.x. [PMID: 1980200] - J J McMurray, C C Lang, D MacLean, D G McDevitt, A D Struthers. Neuroendocrine changes post myocardial infarction: effects of xamoterol.
American heart journal.
1990 Jul; 120(1):56-62. doi:
10.1016/0002-8703(90)90160-y. [PMID: 1972861] - H F Marlow, F L Hine, H M Snow, H Pouleur, M F Rousseau. Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients.
British journal of clinical pharmacology.
1990 May; 29(5):511-8. doi:
10.1111/j.1365-2125.1990.tb03673.x. [PMID: 2140946] - M A James, M Papouchado, K S Channer, J V Jones, H F Marlow, W Bastain, N P Barker, J D Harry, A G Wardleworth. The effect of oral dosing of xamoterol on systolic time intervals in man and xamoterol plasma concentrations in heart failure patients.
British journal of clinical pharmacology.
1990 Apr; 29(4):447-53. doi:
10.1111/j.1365-2125.1990.tb03663.x. [PMID: 2139340] - W Kupper, H H Erlemeier, W Bleifeld. Sympathetic modulation in practice: the German clinical experience.
European heart journal.
1990 Apr; 11 Suppl A(?):19-25. doi:
10.1093/eurheartj/11.suppl_a.19. [PMID: 1971586] - J P Ollivier, I Ricordei, P Bayon, P Popelard, D Moyse, J de Bourayne, C Dupont, J Droniou. Effect of xamoterol on haemodynamics and plasma catecholamines in chronic heart failure.
European heart journal.
1990 Apr; 11 Suppl A(?):59-60. doi:
10.1093/eurheartj/11.suppl_a.59. [PMID: 1971594] - P J de Feyter, P W Serruys, H Suryapranata. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
Circulation.
1990 Feb; 81(2 Suppl):III99-106. doi:
. [PMID: 1967562] - H H Erlemeier, W Kupper, W Bleifeld. [Hemodynamic and humoral changes following intravenous administration of xamoterol in patients with heart failure and coronary heart disease].
Zeitschrift fur Kardiologie.
1990 Feb; 79(2):126-33. doi:
. [PMID: 1969685] - H H Erlemeier, W Kupper, W Bleifeld. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
Cardiology.
1990; 77(1):30-9. doi:
10.1159/000174577. [PMID: 1972349] - M T Kowalski, D Haworth, X Lu, D S Thomson, D B Barnett. Comparison of the effects of xamoterol and isoprenaline on rat cardiac beta-adrenoceptors: studies of function and regulation.
British journal of pharmacology.
1990 Jan; 99(1):27-30. doi:
10.1111/j.1476-5381.1990.tb14648.x. [PMID: 2158836] - D P Nicholls, A J Taggart, J P McCann, W Bastain, R G Shanks. The pharmacokinetics of xamoterol in liver disease.
British journal of clinical pharmacology.
1989 Dec; 28(6):718-21. doi:
10.1111/j.1365-2125.1989.tb03566.x. [PMID: 2532923] - S J Virk, M K Davies. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
British journal of clinical pharmacology.
1989; 28 Suppl 1(?):15S-22S. doi:
. [PMID: 2572250] - W Bastain, H F Marlow. The effect of age and renal impairment on the pharmacokinetics of xamoterol.
British journal of clinical pharmacology.
1989; 28 Suppl 1(?):65S-66S. doi:
10.1111/j.1365-2125.1989.tb03575.x. [PMID: 2572257] - P Y Zech, N Pozet, M A Day, H M Snow, O Madonna, A Hadj-Aissa. Effects of xamoterol on sodium excretion in volunteers.
British journal of clinical pharmacology.
1989; 28 Suppl 1(?):89S-91S. doi:
10.1111/j.1365-2125.1989.tb03584.x. [PMID: 2572266] - E V Sorensen, O Faergeman, M Day, W Bastain. Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.
European journal of clinical pharmacology.
1988; 35(2):183-5. doi:
10.1007/bf00609250. [PMID: 2903827] - W Bastain, M J Boyce, L E Stafford, P B Morton, D A Clarke, H F Marlow. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.
European journal of clinical pharmacology.
1988; 34(5):469-73. doi:
10.1007/bf01046704. [PMID: 2904884] - T Kullmer, W Kindermann, A Urhausen, M Hess. Influence of xamoterol, a partial beta 1-selective agonist, on physical performance capacity and cardiocirculatory, metabolic and hormonal parameters.
European journal of clinical pharmacology.
1988; 34(3):255-62. doi:
10.1007/bf00540952. [PMID: 2899509] - A O Molajo, D H Bennett, H F Marlow, H M Snow, W Bastain. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease.
British journal of clinical pharmacology.
1987 Sep; 24(3):373-9. doi:
10.1111/j.1365-2125.1987.tb03183.x. [PMID: 2889460] - P C Davis. Determination of xamoterol in human plasma by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography.
1987 Jun; 417(1):233-5. doi:
10.1016/0378-4347(87)80114-7. [PMID: 2887582] - H Sato, M Inoue, T Matsuyama, H Ozaki, T Shimazu, H Takeda, Y Ishida, T Kamada. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.
Circulation.
1987 Jan; 75(1):213-20. doi:
10.1161/01.cir.75.1.213. [PMID: 2878742] - G J Mulder, K Groen, R B Tijdens, D K Meijer. Pharmacokinetics of xamoterol glucuronidation in the rat in vivo and in liver perfusion.
Xenobiotica; the fate of foreign compounds in biological systems.
1987 Jan; 17(1):85-92. doi:
10.3109/00498258709047178. [PMID: 2950667] - S Sasayama, S Yokawa, M Akiyama, M Mikawa, O Sakai. Cardiovascular effects of ICI 118,587, a new beta-adrenoceptor partial agonist in man.
Japanese circulation journal.
1986 Jul; 50(7):636-43. doi:
10.1253/jcj.50.636. [PMID: 2877103] - T Hashimoto, A Shiina, T Toyo-Oka, S Hosoda, K Kondo. The cardiovascular effects of xamoterol, a beta 1-adrenoceptor partial agonist, in healthy volunteers at rest.
British journal of clinical pharmacology.
1986 Mar; 21(3):259-65. doi:
10.1111/j.1365-2125.1986.tb05188.x. [PMID: 2421751] - K R Borkowski, P Quinn. Adrenaline and the development of spontaneous hypertension in rats.
Journal of autonomic pharmacology.
1985 Jun; 5(2):89-100. doi:
10.1111/j.1474-8673.1985.tb00109.x. [PMID: 2862149] - H Sato, T Matsuyama, H Ozaki, M Fukushima, M Matsumoto. [Effect of beta 1-partial agonist(ICI 118-587) on plasma catecholamines level and hemodynamics during exercise in congestive heart failure].
Kokyu to junkan. Respiration & circulation.
1984 Nov; 32(11):1159-62. doi:
NULL. [PMID: 6151727] - A O Molajo, M O Coupe, D H Bennett. Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
British heart journal.
1984 Oct; 52(4):392-5. doi:
10.1136/hrt.52.4.392. [PMID: 6148092] - T R Marten, G R Bourne, G S Miles, B Shuker, H D Rankine, V N Dutka. The metabolism of ICI 118,587, a partial agonist of beta 1-adrenoceptors, in mice, rats, rabbits, dogs, and humans.
Drug metabolism and disposition: the biological fate of chemicals.
1984 Sep; 12(5):652-60. doi:
NULL. [PMID: 6149919] - C J Oddie, G P Jackman, A Bobik. Measurement of xamoterol in plasma and urine by high-performance liquid chromatography.
Journal of chromatography.
1984 Jun; 308(?):370-5. doi:
10.1016/s0021-9673(01)87570-1. [PMID: 6146637] - G Jennings, A Bobik, C Oddie, R Restall. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.
Clinical pharmacology and therapeutics.
1984 May; 35(5):594-603. doi:
10.1038/clpt.1984.82. [PMID: 6143634]
